Standout Papers

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 S... 2006 2026 2012 2019 3.5k
  1. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling (2007)
    Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Science
  2. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism (2006)
    Jeffrey A. Engelman, Ji Luo et al. Nature Reviews Genetics
  3. Targeting PI3K signalling in cancer: opportunities, challenges and limitations (2009)
    Jeffrey A. Engelman Nature reviews. Cancer
  4. The PI3K Pathway As Drug Target in Human Cancer (2010)
    Kevin D. Courtney, Ryan B. Corcoran et al. Journal of Clinical Oncology
  5. Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers (2012)
    Ryohei Katayama, Alice T. Shaw et al. Science Translational Medicine
  6. Caveolins, Liquid-Ordered Domains, and Signal Transduction (1999)
    Eric J. Smart, Gregory A. Graf et al. Molecular and Cellular Biology
  7. ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014)
    Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell
  8. Prospects for combining targeted and conventional cancer therapy with immunotherapy (2017)
    Philip J. Gotwals, Scott B. Cameron et al. Nature reviews. Cancer
  9. EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib (2012)
    Ryan B. Corcoran, Hiromichi Ebi et al. Cancer Discovery
  10. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin (2015)
    Matthew G. Oser, Matthew J. Niederst et al. The Lancet Oncology
  11. First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations (2008)
    Lecia V. Sequist, Renato Martins et al. Journal of Clinical Oncology
  12. Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer (2009)
    David M. Jackman, William Pao et al. Journal of Clinical Oncology
  13. Anchored multiplex PCR for targeted next-generation sequencing (2014)
    Zongli Zheng, Matthew Liebers et al. Nature Medicine
  14. PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib (2007)
    Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Cancer Research
  15. Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer (2008)
    Jeffrey A. Engelman, Pasi A. Jänne Clinical Cancer Research
  16. The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics (2015)
    Aaron N. Hata, Jeffrey A. Engelman et al. Cancer Discovery
  17. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer (2013)
    Justin F. Gainor, Anna M. Varghese et al. Clinical Cancer Research
  18. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies (2015)
    Matthew J. Niederst, Haichuan Hu et al. Clinical Cancer Research
  19. CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors (2014)
    Sadhna Vora, Dejan Juric et al. Cancer Cell

Immediate Impact

3 by Nobel laureates 34 from Science/Nature 131 standout
Sub-graph 1 of 18

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
CDK4 and CDK6 kinases: From basic science to cancer therapy
2022 StandoutScience
20 intermediate papers

Works of Jeffrey A. Engelman being referenced

A combinatorial strategy for treating KRAS-mutant lung cancer
2016 Nature
CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
2014 Standout
and 11 more

Author Peers

Author Last Decade Papers Cites
Jeffrey A. Engelman 20979 13540 15823 181 35.4k
William R. Sellers 22311 10319 13505 160 34.1k
William L. Gerald 18572 11903 11849 239 35.4k
Nikolaus Schultz 24300 9694 11479 224 38.0k
Michael J. Eck 18019 11015 12335 156 32.0k
Neal Rosen 24403 5578 12021 255 34.3k
Erik Larsson 21507 6695 8189 207 33.3k
William C. Hahn 26136 4805 11079 289 40.1k
Carlos L. Arteaga 19578 7120 18114 429 34.0k
Kwok‐Kin Wong 17392 7779 10794 271 28.3k
Olli Kallioniemi 19874 7275 9579 419 35.7k

All Works

Loading papers...

Rankless by CCL
2026